Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost, Bimatoprost, and Travoprost for Periocular Skin Pigmentation
NCT00705757Phase 4Completed
- Sponsor
- Summa Health
- Start
- Mar 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Summa Health. Started Mar 2008; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00705757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705757.